Extended DAPT for Multivessel Coronary Artery Disease

To the Editor: Tian and colleagues (July 16 issue) 1 assess whether patients with multivessel coronary artery disease who had been event-free while receiving dual antiplatelet therapy (DAPT) for 12 months after percutaneous coronary intervention (PCI) may benefit from extending DAPT. In the Dual Antiplatelet Therapy in Patients with Coronary Multivessel Disease (DAPT-MVD) trial, 8250 patients were randomly assigned to continue DAPT (clopidogrel plus aspirin) or receive aspirin monotherapy for 12 months. Extending DAPT led to a lower risk of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke (the composite primary efficacy end point) without increasing the risk of . . .